Letter: intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitors. Authors’ reply
Open Access
- 25 June 2020
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (3), 571-572
- https://doi.org/10.1111/apt.15893
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The Usefulness of Fecal Calprotectin in the era of the COVID-19 PandemicGastroenterology, 2021
- Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic reviewJournal of Medical Virology, 2020
- Counter-regulatory ‘Renin-Angiotensin’ System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected PatientsInfectious Disorders - Drug Targets, 2020
- Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?Gastroenterology, 2020
- Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International RegistryGastroenterology, 2020
- 2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseasesAlimentary Pharmacology & Therapeutics, 2020
- Letter: intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitorsAlimentary Pharmacology & Therapeutics, 2020
- Faecal calprotectin indicates intestinal inflammation in COVID-19Gut, 2020
- Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently neededThe Lancet, 2020